EMA starts review of GSK/Vir COVID-19 antibodyThe EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which Share XEMA starts review of GSK/Vir COVID-19 antibodyhttps://pharmaphorum.com/news/ema-starts-review-of-gsk-vir-covid-19-antibody/
Risk of brain clots higher with COVID than vaccine, study suggestsA study has suggested that the risk of getting a serious brain clot is eight to 10 times Share XRisk of brain clots higher with COVID than vaccine, study suggestshttps://pharmaphorum.com/news/risk-of-brain-clots-higher-with-covid-than-vaccine-study-suggests/
Magic mushroom compound matches antidepressant in clinical trialThe active compound in magic mushrooms – psilocybin – seems to be at least as effective as a Share XMagic mushroom compound matches antidepressant in clinical trialhttps://pharmaphorum.com/news/magic-mushroom-compound-matches-antidepressant-in-clinical-trial/
Activist investor Elliott builds stake in GSK after fresh trial upsetActivist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial Share XActivist investor Elliott builds stake in GSK after fresh trial upsethttps://pharmaphorum.com/news/activist-investor-elliott-builds-stake-in-gsk-after-fresh-trial-upset/
NICE recommends Alexion’s long-acting Ultomiris for PNHNICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft Share XNICE recommends Alexion’s long-acting Ultomiris for PNHhttps://pharmaphorum.com/news/nice-recommends-alexions-long-acting-ultomiris-for-pnh/
Microsoft puts AI at heart of digital health strategy with Nuance dealMicrosoft has made its aspirations in digital health clear with a whopping $19.7 billion deal to buy Nuance Share XMicrosoft puts AI at heart of digital health strategy with Nuance dealhttps://pharmaphorum.com/news/microsoft-puts-ai-at-heart-of-digital-health-strategy-with-nuance-deal/
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says RocheRoche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal Share XEvrysdi has ‘real world impact’ on lives of babies with severe SMA, says Rochehttps://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/
AXA partners Microsoft on ‘all-in-one’ digital health platformEuropean insurance giant AXA has stepped up an alliance with Microsoft to develop an international digital health platform Share XAXA partners Microsoft on ‘all-in-one’ digital health platformhttps://pharmaphorum.com/news/axa-partners-microsoft-on-all-in-one-digital-health-platform/
Czech Republic swoops for Denmark’s 2.4m unwanted AZ COVID shotsThe Czech Republic wants to buy around 2.4 million doses of the AstraZeneca/Oxford University vaccine ditched by Denmark, Share XCzech Republic swoops for Denmark’s 2.4m unwanted AZ COVID shotshttps://pharmaphorum.com/news/czech-republic-swoops-for-denmarks-2-4m-unwanted-az-covid-shots/
